Bridge Laboratories Wins Contract From NIDA
Bridge Global Pharmaceutical Services, doing business as Bridge Laboratories, has received a follow-on contract from the National Institute on Drug Abuse.
The single award contract has a five-year base period of performance for an estimated value of $4.1 million if all options are exercised.
Under the new contract, Bridge will provide toxicological evaluations for potential medications used to treat drug abuse.
Tom Oakley, president and CEO of Bridge Laboratories, said: “We appreciate the confidence the National Institute on Drug Abuse (NIDA) has shown in Bridge Laboratories over the past five years and look forward to collaborating with them to find ways to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction.”